Please use this identifier to cite or link to this item:
|Title:||Post-radioembolization yttrium-90 PET/CT-part 2: Dose-response and tumor predictive dosimetry for resin microspheres||Authors:||Kao, Y.-H.
Selective internal radiation therapy
|Issue Date:||2013||Citation:||Kao, Y.-H., Steinberg, J.D., Tay, Y.-S., Lim, G.K.Y., Yan, J., Townsend, D.W., Budgeon, C., Boucek, J.A., Francis, R.J., Cheo, T.S.T., Burgmans, M.C., Irani, F.G., Lo, R.H.G., Tay, K.-H., Tan, B.-S., Chow, P.K.H., Satchithanantham, S., Tan, A.E.H., Ng, D.C.E., Goh, A.S.W. (2013). Post-radioembolization yttrium-90 PET/CT-part 2: Dose-response and tumor predictive dosimetry for resin microspheres. EJNMMI Research 3 (1) : 1-27. ScholarBank@NUS Repository. https://doi.org/10.1186/2191-219X-3-57||Abstract:||Background Coincidence imaging of low-abundance yttrium-90 (90Y) internal pair production by positron emission tomography with integrated computed tomography (PET/CT) achieves highresolution imaging of post-radioembolization microsphere biodistribution. Part 2 analyzes tumor and non-target tissue dose-response by 90Y PET quantification and evaluates the accuracy of tumor 99mTc macroaggregated albumin (MAA) single-photon emission computed tomography with integrated CT (SPECT/CT) predictive dosimetry. Methods Retrospective dose quantification of 90Y resin microspheres was performed on the same 23-patient data set in part 1. Phantom studies were performed to assure quantitative accuracy of our time-of-flight lutetium-yttrium-oxyorthosilicate system. Dose-responses were analyzed using 90Y dose-volume histograms (DVHs) by PET voxel dosimetry or mean absorbed doses by Medical Internal Radiation Dose macrodosimetry, correlated to follow-up imaging or clinical findings. Intended tumor mean doses by predictive dosimetry were compared to doses by 90Y PET. Results Phantom studies demonstrated near-perfect detector linearity and high tumor quantitative accuracy. For hepatocellular carcinomas, complete responses were generally achieved at D70 > 100 Gy (D70, minimum dose to 70% tumor volume), whereas incomplete responses were generally at D70 < 100 Gy; smaller tumors ( 100 Gy more easily than larger tumors. There was complete response in a cholangiocarcinoma at D70 90 Gy and partial response in an adrenal gastrointestinal stromal tumor metastasis at D70 53 Gy. In two patients, a mean dose of 18 Gy to the stomach was asymptomatic, 49 Gy caused gastritis, 65 Gy caused ulceration, and 53 Gy caused duodenitis. In one patient, a bilateral kidney mean dose of 9 Gy (V20 8%) did not cause clinically relevant nephrotoxicity. Under near-ideal dosimetric conditions, there was excellent correlation between intended tumor mean doses by predictive dosimetry and those by 90Y PET, with a low median relative error of +3.8% (95% confidence interval, -1.2% to +13.2%). Conclusions Tumor and non-target tissue absorbed dose quantification by 90Y PET is accurate and yields radiobiologically meaningful dose-response information to guide adjuvant or mitigative action. Tumor 99mTc MAA SPECT/CT predictive dosimetry is feasible. 90Y DVHs may guide future techniques in predictive dosimetry. © 2013 Kao et al.||Source Title:||EJNMMI Research||URI:||http://scholarbank.nus.edu.sg/handle/10635/110218||ISSN:||2191219X||DOI:||10.1186/2191-219X-3-57|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Dec 5, 2022
WEB OF SCIENCETM
checked on Dec 5, 2022
checked on Dec 8, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.